MANDARA: Benralizumab Proves Noninferiority to Mepolizumab for EGPA
The MANDARA trial results, published in NEJM, show benralizumab's noninferiority to mepolizumab in eosinophilic granulomatosis with polyangiitis, with potential for oral glucocorticoid discontinuation.
Michael Wechsler Astrazeneca Media Centre Drug Administration American College Of Rheumatology Office Of The Commissioner National Jewish Health Michael Wechsler
Source: hcplive.com